Walleye Capital’s Relay Therapeutics RLAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.8K Buy
+100
New +$1.92K ﹤0.01% 5848
2025
Q2
– Sell
-101,548
Closed -$266K – 4960
2025
Q1
$266K Sell
101,548
-825,589
-89% -$3.23M ﹤0.01% 3041
2024
Q4
$3.82M Sell
927,137
-892,846
-49% -$4.86M 0.01% 1263
2024
Q3
$12.9M Buy
1,819,983
+1,793,057
+6,659% +$13.4M 0.03% 561
2024
Q2
$176K Buy
+26,926
New +$184K ﹤0.01% 4394
2023
Q4
– Sell
-201,043
Closed -$1.69M – 5425
2023
Q3
$1.69M Buy
+201,043
New +$2.16M ﹤0.01% 1862
2023
Q1
– Sell
-104,000
Closed -$1.55M – 4294
2022
Q4
$1.55M Sell
104,000
-23,049
-18% -$441K 0.03% 712
2022
Q3
$2.84M Buy
+127,049
New +$2.79M 0.05% 396

Other funds holding RLAY

Walleye Capital's RLAY Position: Q3 2026 in Review

Walleye Capital opened a new position in Relay Therapeutics (RLAY) in Q3 2026: 100 shares worth $1.8K. The stake represents ﹤0.01% of the portfolio and ranks #5848 among its holdings. This is a return to the name: Walleye Capital previously reported a position in RLAY as recently as Q1 2025.

Walleye Capital first reported a position in RLAY in Q3 2022 and has held it in 8 quarters since. The position peaked at $12.9M in Q3 2024. 261 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.

  • Walleye Capital held 100 shares of Relay Therapeutics worth $1.8K as of Q3 2026.
  • Relay Therapeutics was a new Walleye Capital position in Q3 2026.
  • Relay Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #5848 holding.
  • Walleye Capital first reported a position in Relay Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • Walleye Capital's Relay Therapeutics position peaked at $12.9M in Q3 2024.
  • 261 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.